Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 2/20 | 0.47 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15842393 | 0.98 | NCF1 (0.95) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL7399656 | 0.98 | NCF1 (0.95) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL10458402 | 0.83 | NCF1 (0.71) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL30760998 | 0.83 | NCF1 (0.71) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL5806618 | 0.81 | NCF1 (0.68) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL12915413 | 0.80 | NCF1 (0.67) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL11671 | 0.80 | NCF1 (0.67) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| Isophthalic Acid SCHEMBL27798934 | 0.80 | NCF1 (0.64) | NCF1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL6645329 | 0.79 | NCF1 (0.65) | NCF1CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL1133878 | 0.79 | NCF1 (0.65) | NCF1CYP1A2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | claimed |
| CN-112390755-B | Heteroaryl method for amine | 中国科学院理化技术研究所 | 2024-08-02 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-104620104-B | Affinity Reagents for Protein Purification | 非凡食品有限公司 | 2017-03-01 | — | — | CN | claimed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | disclosed |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PFIZER INC. (US) | 2024-07-25 | — | — | US | disclosed |
| CN-118271197-A | Cyclohexylamine derivative, and composition and application thereof | 上海京新生物医药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118221644-A | Pyrrolidine derivative, composition and application thereof | 上海京新生物医药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-12006326-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| EP-0091790-A2 | Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines | REILLY INDUSTRIES, INC. (US) | 1983-10-19 | — | — | EP | disclosed |
| US-4405790-A | FROM 3-ALKYLPYRIDINE; SODIUM ALKYLAMIDE | REILLY TAR & CHEMICAL CORP. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4242516-A | Fluorinated amphoteric surfactants | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| US-4161590-A | Fluorinated amphoteric and cationic surfactants | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4161602-A | Fluorinated amphoteric and cationic surfactants containing a pyridinium moiety | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4069244-A | THIO-CARBOXYLIC ACIDS | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4025519-A | HYPOGLYCEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-05-24 | — | — | US | disclosed |
| US-3950524-A | Hypoglycemic benzenesulfonamido pyrimidines | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | NCF1 526/4885CYP1A2 2797/4885NPC1 180/4885 |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PREP, PEPD, ACE | NCF1 3667/4885CYP1A2 831/4885NPC1 1614/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NCF1 3660/4885CYP1A2 1181/4885NPC1 2413/4885 |
| US-12006326-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | NCF1 1437/4885CYP1A2 1080/4885NPC1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.